Recent developments in the discovery of novel oxazolidinone antibacterials

Current Opinion in Drug Discovery and Development

Volumn 8, Issue 4, 2005, Pages 469-477

  Gravestock, Michael B ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Antibacterial resistance; Bioisosteres; Linezolid; Oxazolidinone

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DA 7867; DALFOPRISTIN PLUS QUINUPRISTIN; EPEREZOLID; ERYTHROMYCIN; IMIPENEM; LINEZOLID; MACROLIDE; MCB 3681; MCB 3837; OXAQUIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; PIPERIDYLPHENYLOXAZOLIDINONE; PYRIDOXINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANBEZOLID; UNCLASSIFIED DRUG; VANCOMYCIN; WO 00181350;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; GRAM NEGATIVE INFECTION; HEADACHE; HUMAN; NAUSEA; NONHUMAN; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; THROMBOCYTOPENIA;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; OXAZOLES; OXAZOLIDINONES;

EID: 21444439784     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Harris CR, Thorarensen A. Advances in the discovery of novel antibacterial agents during the year 2002. Curr Med Chem (2004) 11(16):2213-2243. Provides an extremely useful compilation of all research from 2002 on novel antibacterials agents with new mechanisms of action.
2. Bush K, Macielag M, Weidner-Wells M: Taking inventory: Antibacterial agents currently at or beyond phase I. Curr Opin Microbiol (2004) 7(5):466-476. Provides a useful corrective to the popular impression that no new antibacterial agents are currently in development.
3. Phillips OA: Antibacterial agents: Patent highlights January to June 2004. Curr Opin Invest Drugs (2004) 5(8):799-808. Provides a brief summary of new antibacterial patents, with oxazolidinones as one key area.
4. Mukhtar TA, Wright GD: Streptogramins, oxazolidinones and other inhibitors of bacterial protein synthesis. Chem Rev (2005) 105(2):529-542.
5. Barbachyn MR, Ford CW: Oxazolidinone structure-activity relationships leading to linezolid. Angew Chem Int Ed (2003) 42(18):2010-2023. Provides the most comprehensive review of the early SAR in the oxazolidinone series.
6. Hutchinson DK: Oxazolidinone antibacterial agents: A critical review. Curr Top Med Chem (2003) 3(9):1021-1042. Presents a critical review of the SAR and various isosteric replacements for oxazolidinone antibacterial agents, including toxicological aspects.
7. Hutchinson DK: Recent advances in oxazolidinone antibacterial agent research. Expert Opin Ther Pat (2004) 14(9):1309-1328. Provides an important and comprehensive review of all aspects of oxazolidinone research.
8. Nilius AM: Have the oxazolidinones lived up to their billing? Future perspectives for this antibacterial class. Curr Opin Invest Drugs (2003) 4(2):149-155. Presents a brief overview of the oxazolidinone area of research, from the earliest clinical candidates to the present.
9. Eliopoulos GM: Quinpristin-dalfopristin and linezolid: Evidence and opinion. Clin Infect Dis (2003) 36(4):473-481. A useful opinion paper on the merits of quinpristin-dalfopristin and linezolid for serious Gram-positive infections.
10. Chen Y-S, Lee S-C, Kim W-J: Efficacy and tolerability of linezolid in treating severe skin and soft tissue infections caused by Gram-positive pathogens. J Formosan Med Assoc (2004) 103(5):349-354.
11. Ferrara AM, Fietta AM: New developments in antibacterial choice for lower respiratory tract infections in elderly patients. Drugs Aging (2004) 21(3):167-186.
12. Jungbluth GL, Welshman IR, Hopkins NK: Linezolid pharmacokinetics in pediatric patients: An overview. Pediatr Infect Dis J (2003) 22(9 Suppl):S153-S157.
13. Rubinstein E, Isturiz R, Standiford HC, Smith LG, Oliphant TH, Cammarata S, Hafkin B, Le V, Remington J: Worldwide assessment of linezolid's clinical safety and tolerability. Comparator-controlled phase III studies. Antimicrob Agents Chemother (2003) 47(6):1824-1831. Presents an important summary of phase III clinical experience with linezolid.
14. Kuter DJ, Tillotson GS: Hematologic effects of antimicrobials: Focus on the oxazolidinone linezolid. Pharmacotherapy (2001) 21(8):1010-1013.
15. Rao N, Ziran BH, Wagener MM, Santa ER, Yu VL: Similar hematological effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis (2004) 38(8): 1058-1064. Discusses the intriguing observation of a higher incidence of thrombocytopenia associated with vancomycin therapy.
16. Young LS: Hematological effects of linezolid versus vancomycin. Clin Infect Dis (2004) 38(8):1065-1066.
17. Lee E, Burger S, Shah J, Melton C, Mullen M, Warren F, Press R: Linezolid-associated toxic optic neuropathy: A report of 2 cases. Clin infect Dis (2003) 37(10):1389-1391.
18. Ramsay RR, Gravestock MB: Monoamine oxidases: To inhibit or not to inhibit. Mini Rev Med Chem (2003) 3(2):129-136.
19. Reck F, Zhou F, Giradot M, Kern G, Eyermann CJ, Hales NJ, Ramsay RR, Gravestock MB: Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A. J Med Chem (2005) 48(2):499-506.
20. Meka VG, Gold HS: Antimicrobial resistance to linezolid. Clin Infect Dis (2004) 39(7):1010-1015. Presents a comprehensive summary of the genetic basis for linezolid resistance development in laboratory and clinical bacterial strains.
21. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, Moellering RC, Ferraro MJ: Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet (2001) 358(9277):207-208. Provides the first description of clinical resistance to linezolid.
22. Ruggero KA, Schroeder LK, Schreckenberger PC, Mankin AS, Quinn JP: Nosocomial superinfections due to linezolid-resistant Enterococcus faecalis: Evidence for a gene dosing effect on linezolid MICs. Diagn Microbiol Infect Dis (2003) 47(3):511-513.
23. Colca JR, McDonald WG, Waldon DJ, Thomasco LM, Gadwood RC, Lund ET, Cavey GS, Mathews WR, Adams LD, Cecil ET, Pearson JD et al: Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J Biol Chem (2003) 278(24):21972-21979. Provides an important resolution of earlier conflicting claims to the location of the oxazolidinone binding site.
24. Kim HY, Lee JS, Cha JH, Pae AN, Cho YS, Chang MH, Koh HY: Synthesis and in vitro activity of new methylenepiperidinyl and methylenepyrrolidinyl oxazolidinone antibacterial agents. Bioorg Med Chem Lett (2003) 13(13):2227-2230.
25. Xu J, Golshani A, Aoki H, Remme J, Chosay J, Shinabarger DL, Ganosa MC: Protected nucleotide G2608 in 23S rRNA confers resistance to oxazolidinones in E coli. Biochem Biophys Res Comm (2005) 328(2):471-476.
26. Gordeev MF, Hackbarth C, Barbachyn MR, Banitt LS, Gage JR, Luehr GW, Gomez M, Trias J, Monn SE, Zurenko GE, Parker CN et al: Novel oxazolidinone-quinolone hybrid antimicrobials. Bioorg Med Chem Lett (2003) 13(23):4213-4216.
27. Hubschwerlen C, Specklin J-L, Baeschlin DK, Borer Y, Haefeli S, Sigwalt C, Schroeder S, Locher HH: Structure-activity relationship in the oxazolidinone-quinolone hybrid series: Influence of the central spacer on the antibacterial activity and the mode of action. Bioorg Med Chem Lett (2003) 13(23):4229-4233. Discusses some important aspects of the SARs for these new hybrid species.
28. Barbachyn MR, Cleek GJ, Dolak LA, Garmon SA, Morris J, Seest EP, Thomas RC, Toops DS, Watt W, Wishka DG, Ford CW et al: Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens. J Med Chem (2003) 46(2):284-302. Provides a definitive description of the research leading to the discovery of the major oxazolidinone bioisostere isoxazoline ring system.
29. Snyder LB, Meng Z, Mate R, D'Andrea SV, Marinier A, Quesnelle CA, Gill P, DenBleyker KL, Fung-Tomc JC, Frosco M, Martel A et al: Discovery of isoxazolinone antibacterial agents. Nitrogen as a replacement for the stereogenic center found in oxazolidinone antibacterials. Bioorg Med Chem Lett (2004) 14(18):4735-4739.
30. Mathur T, Singhal S, Khan S, Upadhyay D, Yadav A, Rudra S, Das B, Rattan A: Ranbezolid (RBx-7644) has concentration-dependent bactericidal activity against anaerobes. 44th ICAAC Meeting, Washington, DC, USA (2004): Abs F-1416.
31. Yong D, Yum JH, Lee K, Chong Y, Choi SH, Rhee JK: In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria. Antimicrob Agents Chemother (2004) 48(1):352-357.
32. Jo YW, Im WB, Rhee JK, Shim MJ, Kim WB, Choi EC: Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with a heteroaromatic ring. Bioorg Med Chem (2004) 12(22):5909-5915.
33. Probiodrug AG: Morphochem and Probiodrug collaborate in research and development of novel innovative dipeptidyl peptidase IV (DP IV) inhibitors for the treatment of anxiety and depression. Press Release (2004) November 18. http://www.probiodrug.de/index. asp?action=swtext&la=5001&id=446
34. PHARMACIA & UPJOHN CO (Martin JP Jr, Dupuis MJ, Herberg JT): Cotherapy with an oxazolidinone and a vitamin B. WO-03063862 (2003). This patent could be an important pointer to future treatment options with oxazolidinone therapy.
35. Chugh Y, Shetty N, Deshpande PK, Sindkhedkar MD, Jafri MA, Yeole RD, Shukla MC, Gupte SV, Patel MV, De Sousa NJ: Antimicrobial oxazolidinones with improved pharmacokinetic profile and safety advantages. WO-2004007488 (2004). Provides an intriguing filing containing reticulocyte data to support claims that representative compound 6 (Figure 2) exhibits lower myelosuppressive potential than linezolid with once-daily doses.
36. MERCK & CO INC/KYORIN PHARMACEUTICAL CO LTD (Fukuda Y): Cyclopropyl hexane containing oxazolidinone antibiotics and derivatives thereof. WO-03048136 (2003). Discloses compounds with excellent potency on Gram-positive pathogens, but no data to support superior toxicity claims is included.
37. ASTRAZENECA AB (Gravestock MB, Hales NJ, Reck F, Zhou F, Fleming PR, Carcanague DR, Giradot MM): 3-Cyclyl-5-(nitrogen-containing 5-membered ring) methyl-oxazolidinone derivatives and their use as antibacterial agents. WO-03072575 (2003).
38. Patel MV, Deshpande PK, Sindkhedkar MD, Gupte SV, Chugh Y, Shetty N, Shukla MC, Yeole RD, De Sousa NJ: Antibacterial cyano-(substituted)- methylenepiperidinophenyl oxazolidinones targeting multiple hbonucleoprotein sites. WO-2004007489 (2004). Provides an interesting filing with claims for bactericidal activity and at additional binding sites.
39. WARNER-LAMBERT CO LLC (Chupak LS, Kaneko T, Josyula VP, Kim J-Y, Choy AL, Hagen SE, Boyer FE Jr): Antibacterial agents. WO-2004069832 (2004).
40. WARNER-LAMBERT CO LLC (Chupak LS, Kaneko T, Josyula VP, Jiao W): Oxazolidinone derivates N-substituted by a tricyclic ring, for use as antibacterial agents. WO-2004069245 (2004).
41. WARNER-LAMBERT CO LLC (Chupak LS, Kaneko T, Josyula VP, Pettersson MJ, Lall MS, Hagen SE, Boyer FE Jr): Oxazolidinone derivatives N-substituted by a bicyclic ring, for use as antibacterial agents. WO-2004069244 (2004).
42. PHARMACIA & UPJOHN CO (Hester JB Jr, Adams WJ, Stevens JC, Scott C, Gordeev MF, Singh U): Glycoloyl-substituted oxazolidinone-derivatives as antibacterial agents. WO-2004002479 (2004). Re-use of earlier dihalo-substituted amide side chains including the novel 1,1-difluoromethylthioacetamide group.
43. PHARMACIA & UPJOHN CO (Gordeev MF, Singh U, Patel DV, May PD): Antimicrobial 1-aryl dihydropyridone compounds. WO-2004033449 (2004).
44. MERCK & CO INC/KYORIM PHARMACEUTICAL CO LTD (Fukuda Y. Hammond ML): Bicyclo[3,1,0]hexane-containing oxazolidinone antibiotics and derivatives thereof. WO-03027083 (2003). Discloses compounds having outstanding Gram-positive antibacterial activity and also activity against Chlamydial and Mycobacterial strains.
45. ASTRAZENECAAB (Gravestock MB, Hales NJ, Swain ML, Hauck SI, Mills SD): Oxazolidinones and/or isoxazolines as antibacterial agents. WO-03022824 (2003).
46. VITA-INVEST SA (Mancini M, Marisabel HC, Hidalgo RJ, Del Castillo JC): Novel oxazolidinone derivatives useful as antibacterial agents. WO-03002560 (2003).
47. MORPHOCHEM AG FÜR KOMBINATORISCHE CHEMIE (Hubschwerlen C, Speckilin J-L, Baeschlin DK, Locher H, Sigwalt C): Use of oxazolidinone-quinolone hybrid antibiotics for the treatment of anthrax and other infections. WO-2004096221 (2004). Provides the most successful realization of the fluoroquinolone- oxazolidinone hybrid concept to date.
48. RIB-X PHARMACEUTICALS INC (Wang D, Sutcliffe JA, Oyelere AK, McConnell TS, Ippolito JA, Abelson JN): Bifunctional heterocyclic compounds and methods of making and using them. WO-2004029066 (2004). Contains comprehensive claims to many macrolide-antlbacterial hybrids, including oxazolidinones.
49. LABORATORIOS SALVAT SA (Farerons Gallemi C, Laguna Arnal C, Fernandez Serrat A, Catena Ruiz JL, Miquel Bono IJ, Balsa Lopez D, Salcedo Roca C, Toledo Mesa N, Fernandez Garcia A): Substituted isoxazoles and the use thereof as antibiotics. WO-03008395 (2003).
50. DR REDDY'S LABORATORIES LTD (Mohamed T, Das J, Natesan S, Trehan S, Igbal J, Magadi SK): Novel antiinfective compounds and their pharmaceutical compositions. WO-2004106329 (2004).